is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
P-MEC China, co-organized by Informa Markets, CCCMHPIE and Sinoexpo Informa Markets, will take place at the Shanghai New International Expo Center (SNIEC) on 22-24 June 2020. The event will be co-located with CPhI China with total area exceeding 210,000m2 and over 75,000 visits of professionals are expected.
The implementation of the “Healthy China 2030” Planning Outline has ushered in rapid development of China’s big health industry, with the industry scale expected to reach RMB8.78 trillion in 2019 and RMB14.09 trillion in 2023, calculated as per the about 12.55% compound annual growth rate in the next five years.
Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
Find out why the Istanbul Chamber of Commerce (ICOC) is coming to CPhI & P-MEC China this year and read why China is such an important market for Turkish businesses to tap into.
Find out why the Polish Investment and Trade Agency (PAIH) is coming to CPhI & P-MEC China this year and read why China is such an important market for Polish businesses to tap into.
New analysis released ahead of CPhI & P-MEC China – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
Interview with: Killian O'Driscoll, Director of Projects, National Institute for Bioprocessing Research and Training (NIBRT). It is widely acknowledged that China is going to play a significant role in both the production and consumption of biopharmaceuticals over the next decade. If the Chinese BioPharma market continues to grow at pace, a consistent pipeline of talent is needed to sustain it.
Significant increase in exhibitors driven by bio growth at bioLIVE and separate nutraceuticals event. One of the key trends to emerge this year is the rise in the number of innovative China-based biotechs – coupled with the easing of regulatory pathways and an emerging CDMO sector – is fueling a significant growth in manufacturing across China.
Chinese pharmaceutical stocks jumped after the government said it plans to expand tax breaks to rare-disease treatments and speed the approval process for cancer drugs. The CSI 300 index of health-care stocks traded in Shanghai and Shenzhen advanced 3.1 percent on Tuesday (February 12th, 2019), to the highest level in two months.
With the improvement of people’s living standards and the transformation of consumption structure, the focus on diseases has shifted from simple treatment to prevention in recent years. Plant extracts, as the core raw materials and products of biopharmaceuticals, have been widely applied in botanical drugs, food additives, functional foods, health foods, and cosmetics, etc.
The market size of the Chinese health food industry is expected to reach about RMB403.6 billion in 2020. The active natural extracts have played a vital role in the process of acceleration of the entire nutrition and health food industry and the gradual maturity of the market, and the flourishing of the nutrition and health food industry has brought the steadily growing demand for the natural extract industry.
According to a recent Freedonia market research report, the demand for global pharmaceutical packaging solutions is growing at a rate of approximately 6% per year, with the market projected to reach a value of USD 112 billion by 2021. The Global Pharmaceutical Packaging report reveals the drivers behind this significant market growth, including an aging population and increased prevalence of acute and chronic disease.
What does 2019 have in store for Pharma? We asked industry Thought Leaders to name one disruptive trend or technology that will have a significant impact on the market in the year ahead.
Will pricing pressure lead to a shift in budget management? Is this the year for biosimilar approvals? Will we see continued M&A activity in the sector? From life cycle management to AI, and Supergenerics to digital healthcare, we’ve listed the Pharma and Biopharma trends you need to know about for 2019.
According to He Liming, some period in the future will be the key period for the quality and efficiency improvement of the pharmaceutical logistics industry of China. The pharmaceutical logistics industry is closely related to people’s health, and has big development space; the sustained and rapid development of the industry is of positive significance to improving the health security and securing a decisive victory in building a moderately prosperous society in all respects.
Animal Health & Feed Zone of CPhI China 2019 to Build a New Benchmark for the Industry. Size of the global veterinary drug market continues to grow as the market continues to develop. According to the forecast of the Forward Industry Research Institute, size of the global veterinary drug market will maintain about 7.3% average annual growth from 2017 to 2022, and is expected to reach RMB537.2 billion in 2022.
Still scratching your head, wondering about “which materials are fit for pharmaceutical products” and “how to improve the humanized design of drug delivery devices”?The most suitable products will appear before you when the time is right! This seems to be “Buddhist-style”, but it is the idealistic scene to every researcher and purchaser.
World’s First Batch of Pharmaceutical Equipment Intelligent Manufacturing Plants. Truking Technology, together with the controlling shareholders, acquired the world famous pharmaceutical equipment enterprise: German Romaco in April 2017, to establish Sino-German complementation and product complementation, form the unique pattern in the industry, and greatly advance the international development of the enterprise.
The Amendment of the Drug Administration Law of the People's Republic of China (Draft for Comment) proposes to cancel the GMP certification and GSP certification, and change the APIs and excipients to be approved together with pharmaceutical products.